Hepatitis C virus infection in inclusion body myositis: A case-control study

Neurology

Volumn 86, Issue 3, 2016, Pages 211-217

  Uruha, Akinori ^a,b   Noguchi, Satoru ^a,b   Hayashi, Yukiko K ^a,b,c   Tsuburaya, Rie S ^b   Yonekawa, Takahiro ^b   Nonaka, Ikuya ^a,b   Nishino, Ichizo ^b  

^a Medical Genome Center   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS PROTEIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; INCLUSION BODY MYOSITIS; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; PHYSICIAN; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; COMORBIDITY; JAPAN; MIDDLE AGED; MYOSITIS, INCLUSION BODY; PATHOLOGY; VIROLOGY;

AGED; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; JAPAN; MALE; MIDDLE AGED; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; PREVALENCE;

EID: 84955284413     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002291     Document Type: Article

References (31)

1. Benveniste O, Stenzel W, Hilton-Jones D, et al. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol 2015;129:611-624.
2. Mastaglia FL, Needham M. Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J Clin Neurosci 2015;22:6-13.
3. Suzuki N, Aoki M, Mori-Yoshimura M, et al. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol 2012;259:554-556.
4. Alexander JA, Huebner CJ. Hepatitis C and inclusion body myositis. Am J Gastroenterol 1996;91:1845-1847.
5. Kase S, Shiota G, Fujii Y, et al. Inclusion body myositis associated with hepatitis C virus infection. Liver 2001;21:357-360.
6. Tsuruta Y, Yamada T, Yoshimura T, et al. Inclusion body myositis associated with hepatitis C virus infection. Fu-kuoka Igaku Zasshi 2001;92:370-376.
7. Yakushiji Y, Satoh J, Yukitake M, et al. Interferon beta-responsive inclusion body myositis in a hepatitis C virus carrier. Neurology 2004;63:587-588.
8. Warabi Y, Matsubara S, Mizutani T, et al. Inclusion body myositis after interferon-alpha treatment in a patient with HCV and HTLV-1 infection [in Japanese]. Rinsho Shin-keigaku 2004;44:609-614.
9. Alverne AR, Marie SK, Levy-Neto M, et al. Inclusion body myositis: series of 30 cases from a Brazilian tertiary center [in Portuguese]. Acta Rheumatol Port 2013;38:179-185.
10. Rose MR; ENMC IBM Working Group. 188th ENMC International Workshop: inclusion body myositis, 2-4 December 2011, Naarden, the Netherlands. Neuromuscul Disord 2013;23:1044-1055.
11. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyo-sitis. Lancet 2003;362:971-982.
12. Rodríguez Cruz PM, Luo YB, Miller J, et al. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Dis-ord 2014;24:1025-1035.
13. Malicdan MC, Noguchi S, Nishino I. Monitoring autophagy in muscle diseases. Methods Enzymol 2009; 453:379-396.
14. Walker FM, Dazza MC, Dauge MC, et al. Detection and localization by in situ molecular biology techniques and immunohistochemistry of hepatitis C virus in livers of chronically infected patients. J Histochem Cytochem 1998;46:653-660.
15. Tanaka J, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004;47:32-40.
16. Cupler EJ, Leon-Monzon M, Miller J, et al. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-1893.
17. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 2006;66(2 suppl 1): S33-S38.
18. Dalakas MC, Rakocevic G, Shatunov A, Goldfarb L, Raju R, Salajegheh M. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol 2007;61:466-475.
19. Ozden S, Gessain A, Gout O, et al. Sporadic inclusion body myositis in a patient with human T cell leukemia virus type 1-associated myelopathy. Clin Infect Dis 2001; 32:510-514.
20. Matsuura E, Umehara F, Nose H, et al. Inclusion body myositis associated with human T-lymphotropic virus-type I infection: eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol 2008;67:41-49.
21. Galossi A, Guarisco R, Bellis L, Puoti C. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 2007;16:65-73.
22. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013; 369:1035-1045.
23. Zampino R, Marrone A, Restivo L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013;5: 528-540.
24. Münz C, Lünemann JD, Getts MT, et al. Antiviral immune responses: triggers of or triggered by autoimmu-nity? Nat Rev Immunol 2009;9:246-258.
25. Hiepe F, Dörner T, Hauser AE, et al. Long-lived autor-eactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011;7:170-178.
26. Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoanti-bodies to cytosolic 59-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013;73:397-407.
27. Larman HB, Salajegheh M, Nazareno R, et al. Cytosolic 59-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013;73:408-418.
28. Wu S, Kanda T, Nakamoto S, et al. Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One 2013;8:e73615.
29. Ministry of Health, Labor and Welfare, Japan. Present Situation and Measure on HTLV-1 [in Japanese]. Available at: http://www.google.co.jp/url?sa=t&rct=j&q =&esrc=s&source=web&cd=1&ved=0CB8QFjAA&url =http%3A%2F%2Fwww.kantei.go.jp%2Fjp%2Fsingi%2Fhtlv%2Fdai1%2Fgenjoutotaisaku.pdf&;ei=k7wLV fOTGYih8QXkyYE4&usg=AFQjCNHI9ZlSte2X-4gha7X4w9ImExasWg&sig2=Ut8RUL-hqKk8WB=aVaAX mg&bvm=bv.88528373,d.dGc. Accessed March 27, 2015.
30. Desdouits M, Cassar O, Maisonobe T, et al. HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa. J Clin Virol 2013;57:70-76.
31. Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myo-sitis. Neurology 2014;83:426-433.